Domain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology Company

STRASBOURG, France & MONTREAL & BOSTON--(BUSINESS WIRE)--Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the appointments of Michael Gottlieb, as its Chairman of the Board of Directors, and Anthony Johnson, M.D., as its President and Chief Executive Officer. Michael’s appointment as Chairman follows Laurence Rulleau and Yousse